Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05502250 |
Title | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL) |
Acronym | HOVON164HL |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Stichting Hemato-Oncologie voor Volwassenen Nederland |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | NLD | DNK | BEL |